Long-term imatinib therapy promotes bone formation in CML patients.

@article{Fitter2008LongtermIT,
  title={Long-term imatinib therapy promotes bone formation in CML patients.},
  author={Stephen Fitter and Andrea L Dewar and Panagiota Kostakis and Luen Bik To and Timothy P Hughes and Marion M Roberts and Kevin Lynch and Barrie Vernon-Roberts and Andrew C W Zannettino},
  journal={Blood},
  year={2008},
  volume={111 5},
  pages={2538-47}
}
Imatinib inhibits tyrosine kinases important in osteoclast (c-Fms) and osteoblast (platelet-derived growth factor receptor [PDGF-R], c-Abl) function, suggesting that long-term therapy may alter bone homeostasis. To investigate this question, we measured the trabecular bone volume (TBV) in iliac crest bone biopsies taken from chronic myeloid leukemia (CML) patients at diagnosis and again after 2 to 4 years of imatinib therapy. Half the patients (8 of 17) showed a substantive increase in TBV (> 2… CONTINUE READING